Cardiovascular Systems to Present 12-Month Data From COMPLIANCE 360° Study at ACC
March 12 2012 - 8:00AM
Business Wire
Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), will present
12-month data from its COMPLIANCE 360° study at The American
College of Cardiology’s (ACC's) 61st Annual Scientific Session
& Expo, McCormick Place South, in Chicago, March 24–27, 2012.
The COMPLIANCE 360° study is comparing treatment of above-the-knee
calcified lesions using CSI’s Diamondback™ Orbital Atherectomy
System, followed by low-pressure balloon angioplasty, to balloon
angioplasty alone.
ACC Abstract Discussion: March
24
WHAT: Principal Investigator of the COMPLIANCE 360°
study, Dr. Raymond Dattilo, St. Francis Health Center, Topeka,
Kan., will present 12-month data in a poster session (Abstract
Presentation #1123-37).
The COMPLIANCE 360° trial is a prospective, randomized study
that examines whether CSI’s Diamondback Orbital Atherectomy System
can achieve satisfactory acute and long-term results without the
need for stent placement. In the COMPLIANCE 360° study, 50 patients
were enrolled at nine U.S. sites. The Diamondback System is a
minimally invasive orbital atherectomy system indicated for use as
therapy in patients with peripheral arterial disease (PAD) –
blockages in leg arteries.
WHEN:
Saturday, March 24, 9:30 a.m.
WHERE:
McCormick Place South, Hall A
The CV Innovations Educational Forum:
March 25
WHAT: CSI will participate in the International Society
of Cardiovascular Translational Research’s Cardiovascular (CV)
Innovations Forum with two panel discussions composed of industry
thought leaders. Physicians, researchers and FDA representatives
will discuss advanced treatment of calcium in peripheral and
cardiovascular disease.
WHEN:
Sunday, March 25:
•
12:15 p.m.: Challenges Associated with
Treating Calcified Coronary Artery Disease
•
1:10 p.m.: Current Approach for Treating
Calcified Peripheral Arterial Disease
WHERE:
CV Innovations Educational Forum, CV
Theater, #22097McCormick Place South, Hall A2
CSI Booth at ACC: March
24–26
Visit CSI at booth #9078, 9:30 a.m. – 4:45 p.m. Saturday, March
24, through Monday, March 26.
ABOUT PAD: PAD is a life-threatening condition where a
fatty material called plaque builds up on the inside walls of the
blood vessels that carry blood from the heart to legs and arms. The
plaque buildup causes the arteries to harden and narrow
(atherosclerosis), reducing blood flow to the legs. The risk of PAD
increases if a person has one or several of the following: high
blood pressure, abnormal cholesterol levels, diabetes, or personal
history of heart disease, heart attack or stroke. More than 12
million people in the United States suffer from PAD. With risk
factors such as diabetes and obesity on the rise, the prevalence of
PAD is growing at double-digit rates.
About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a
medical device company focused on developing and commercializing
innovative solutions for treating vascular and coronary disease.
The coronary system is limited by federal law to investigational
use and is currently not commercially available in the United
States.
For more information visit the company’s Website at
www.csi360.com.
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From Jul 2023 to Jul 2024